Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amgen (NQ: AMGN )

289.90 +2.03 (+0.71%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amgen

< Previous 1 2 3 4 5 6 7 8 9
...
47 48 Next >
Why Big-Name Biotech Regeneron Pharma Just Joined The 1,000-Club
Enthusiasm is growing for a looming approval in COPD treatment. 
Via Investor's Business Daily
Skye Bioscience Pivots To Obesity After Glaucoma Flop; Shares Plummet
The company is focusing on obesity treatment after its glaucoma drug failed. 
Via Investor's Business Daily
Is Geron Stock a Buy Following Its First New Drug Approval?
Find out if the high-flying biotech stock can keep on climbing higher. 
Via The Motley Fool
Market Whales and Their Recent Bets on AMGN Options
Via Benzinga
Amgen Seeks Expanded US Approval For Autoimmune Disease Drug Acquired Via $28B Horizon Deal
Amgen announced Phase 3 trial results for Uplizna for IgG4-related disease, achieving an 87% reduction in flare risk. All key secondary endpoints were met with no new safety signals. 
Via Benzinga
The Gold Rush for Weight Loss Drugs Is Here. These 3 Latecomers Could Be Worth a Buy.
There's probably a big enough pie here for everyone to get a slice. 
Via The Motley Fool
Here's How Much You Would Have Made Owning Amgen Stock In The Last 20 Years
Via Benzinga
Where Will Amgen Be in 3 Years?
The Amgen of 2027 could be much be larger than some investors expect. 
Via The Motley Fool
If You Invested $1000 In This Stock 20 Years Ago, You Would Have $5,700 Today
Via Benzinga
Amgen Secures FDA Nod For Rare-Disease Treatment Biosimilar Based On AstraZeneca's Drug
The FDA has approved Amgen's Bkemv as the first interchangeable biosimilar to AstraZeneca's Soliris for treating rare diseases. 
Via Benzinga
Exposures Product Safety
OZEM ETF: 7 Things to Know About the New Roundhill GLP-1 & Weight Loss ETF
As weight loss drugs are gaining popularity Roundhill GLP 1 And Weight Loss ETF (OZEM) has launched as anew way to invest in them. 
Via InvestorPlace
Topics ETFs
Amgen's Catching Up to Novo Nordisk and Eli Lilly. Should You Buy It?
The gold rush for obesity medications just got a bit more intense. 
Via The Motley Fool
What's Going On With Mid-Cap Cancer-Focused Verastem Oncology Stock On Friday?
Verastem Oncology reports promising initial results from the RAMP 205 trial with an 83% ORR for avutometinib and defactinib in metastatic pancreatic cancer. FDA submission for recurrent KRAS mutant... 
Via Benzinga
Exposures Product Safety
Stocks to Buy: 7 Undeniable Dow Darlings to Pile Into Now
Most Dow stocks are strong investments but these 7 stand out at the moment as the macroenvironment trends positive again. 
Via InvestorPlace
Topics Stocks
Exposures US Equities
Amgen Unusual Options Activity
Via Benzinga
EXCLUSIVE: Roundhill Investments Launches Weight Loss ETF For Exposure To Blockbuster Drugs Like Ozempic
Roundhill CEO Dave Mazza says investors "can't just buy a basket of big pharma names or a broad-based biotech ETF and call it a day." 
Via Benzinga
Topics ETFs
7 Reliable Blue-Chip Stocks That Cannot Miss
These reliable blue-chip stocks to own are the closest thing to slam dunk investments that exist. Discover why you should buy them now. 
Via InvestorPlace
Amgen/AstraZeneca Say Asthma Drug Shows Activity In Another Lung Disease Across Broad Patient Population
Amgen and AstraZeneca reveal Phase 2a results for Tezspire in severe COPD, showing a 17% reduction in exacerbations, with notable improvements in lung function and quality of life for patients with... 
Via Benzinga
7 Biotech Stocks That Could Breathe New Life Into Your Portfolio
Thanks to the underlying pertinence, these established biotech stocks to buy offer confidence to investors facing tricky market conditions. 
Via InvestorPlace
Dow Jones Industrial Average Closes Above 40,000 In Quiet Friday Climb
The Dow Jones Industrial Average closed above the 40,000.00 major handle for the first time ever after markets wound down a hectic trading week that saw rate cut hopes return to the forefront after US... 
Via Talk Markets
Topics Economy Stocks
Exposures Interest Rates US Equities
Is Amgen a Threat to Eli Lilly in This Billion-Dollar Market?
Eli Lilly's biggest growth drivers today are its weight loss drugs. 
Via The Motley Fool
Cannabis Meets Prescription Drugs, Steroids And Ketamine In Schedule III: What It Means, Key Stocks To Watch
President Joe Biden's administration is moving to reschedule cannabis from Schedule I to Schedule III under the Controlled Substances Act (CSA). 
Via Benzinga
Topics Cannabis
Exposures Cannabis
Pharma Stocks Outlook: Where Are 2024’s Top Performers Headed Next?
Investors want to know where 2024's top-performing pharma stocks are headed in the second half of the year for good reason. 
Via InvestorPlace
FDA Gives Accelerated Approval To Amgen's Drug For Small Cell Lung Cancer Patients
FDA approves Amgen's Imdelltra for treating ES-SCLC, based on response rate and DoR in clinical studies. Approval may depend on further trials. 
Via Benzinga
Exposures Product Safety
Meet the GLP-1 Drug That Could Be the Biggest Concern for Eli Lilly and Novo Nordisk
Could Amgen be the next stock to soar due to a GLP-1 drug? 
Via The Motley Fool
S&P 500, Nasdaq 100, Dow Jones Shatter Record Highs In Unstoppable Bull Market Rally
The S&P 500, Nasdaq 100 and Dow Jones Industrial Average indices all shattered fresh all-time highs Wednesday, driven by a benign inflation report that boosted risk sentiment among bullish investors. 
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
The 3 Best Dow Stocks to Buy in May 2024
The Dow Jones Industrial Average has been on a hot streak this month. Here are the three best Dow stocks to buy. 
Via InvestorPlace
Topics Stocks
Exposures US Equities
Amgen Is Working On a Wegovy Competitor -- What It Means for Investors
The biotech's pipeline extends far beyond this exciting weight-loss product. 
Via The Motley Fool
5 Stocks Driving Dow's Market-Beating Performance
While 27 of the 30 members of the Dow Jones Index have performed well over the last seven days, we have highlighted five of them that have been leading the way higher. 
Via Talk Markets
Topics Stocks
Exposures US Equities
7 Weight Loss Drug Stocks Poised for Explosive Growth by 2025
The second wave of the weight loss drug stock boom is underway and investors should heed the signs the market is serving. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9
...
47 48 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback